Drugs / Influenza Vaccines
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00848887 | Oct 2008 → May 2009 | influenza | Novartis | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04591379 | Feb → Sep 2021 | colorectal cancer | Zealand University Hospital | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06038617 | Oct 2023 → Apr 2025 | — | Duke University | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-08-03 | Novartis Pharmaceuticals | Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | influenza vaccines | “Pneumococcal, DTaP, Haemophilus Influenzae Type B, MMR, Varicella, MMRV, Hepatitis A, Inactivated Poliovirus, Hepatitis B, Rotavirus, Influenza vaccines” NCT06038617 ↗ |
| Modality | Vaccine | “different combinations of adjuvanted (ATIV) and non-adjuvanted trivalent (TIV) and quadrivalent (QIV) influenza vaccines” PMID 21906647 ↗ Sep 2011 |